Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
Conditions
Interventions
Intervention1: Levonadifloxacin Injection 800 mg Levonadifloxacin tablet 500 mg: Levonadifloxacin IV 800 mg will be administered twice in a day 11±1 hours apart. One dose of IP will be infused over a
Sponsors
Dr Anand Nikalje
Wockhardt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult subjects of any gender >=18 years 2. Subjects must be willing to participate in the study and provide a written informed consent 3. Subjects with diagnosed ABSSSI (requiring hospitalization) characterized by any of the following infection types: a. Cellulitis / Erysipelas: diffuse skin infection characterized by spreading areas of redness, oedema and induration b. Wound infection: An infection characterized by purulent drainage from a wound with surrounding redness, oedema and / or induration c. Major cutaneous abscess: An infection characterized by a collection of pus within the dermis or deeper that was accompanied by redness, oedema and/or induration d. Diabetic foot infection 4. Subjects with lesion size area of at least 75 cm2, lesion size was measured by the area of redness, oedema or induration 5. Subjects with suspected and / or documented evidence of Gram positive infection
Exclusion criteria
Exclusion criteria: 1.Subjects with history of hypersensitivity to any of the study drugs or same class of drugs 2.Subjects who have received prior antibiotic therapy within the past 24 hours for the treatment of a current episode of ABSSSI. Followings are the exception to these criteria: a.Subjects who have received a single dose of short acting antibacterial drug within 24 hours of enrolment b.Subjects with evidence of clinical progression of ABSSSI while on antibacterial drug therapy after at least 48 hours c.Subjects who have received an antibacterial drug for surgical prophylaxis and subsequently developed ABSSSI 3.Subjects who received any experimental drug within 30 days prior to enrolment 4.Subjects who, in the judgment of the Investigator, are likely to be noncompliant or uncooperative during the study 5.Subjects with any abnormality that the Investigator deems to be clinically relevant, either on medical history, systemic examination, or ECG, 6.Subjects on hemodialysis or creatinine clearance Subjects with abnormal platelet count
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical success rate at TOC (Test of Cure) visitTimepoint: Day 7±1 to 14 from initiation of therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical success rate at EOT (End of Treatment) visit i.e. Day 7±1 to 14 Clinical improvement rate at visit 2 (Early Assessment visit) i.e. Day 4±1 from initiation of therapy Microbiological success rate at EOT (End of Treatment) visit Safety â?? Tolerability Endpoint: Incidence of adverse events or serious adverse events Incidence of Nephrotoxicity & Incidence of ThrombocytopeniaTimepoint: Day 7±1 to 14 Day 4±1 from initiation of therapy Day 7±1 up to Day 14 Throughout the study | — |
Countries
India
Contacts
Public ContactDr Khokan Debnath
Wockhardt Ltd.
Outcome results
None listed